Key Takeaways
- Strong revenue growth, steady margins: Operating revenue grew 31% YoY on balanced volume and price contributions, while cost-plus contract structures kept EBITDA margins in the 26–28% sustainable range.
- Fluorination pipeline is the big bet: 14 molecules identified with $220–260 mn annual revenue potential, with 5 commercializing this year from existing capacity, requiring no fresh CAPEX.
- Working capital elevated by design: Customers asked Anupam to hold precautionary inventory during supply disruption, inflating working capital; management expects significant reduction by year-end and confirms no price or volume risk on that stock.
- Japan emerges as a growth axis: Japan revenue share rose from 1% in 2018 to 13% in Q1 FY23, with a leading Japanese MNC added during the quarter.
- What to watch next quarter: Pace of inventory unwind, progress on fluorination commercialization, and whether the LOI pipeline converts into signed contracts as guided.
Revenue Growth & Drivers
- Volume and price both contributed: Q1 growth was fairly split between volume and price, with customers revising volume guidance upward despite price increases because Anupam maintained consistent supplies through volatility.
- Life Sciences dominance: The segment contributed 95% of total revenue; Other Specialty Chemicals declined from ₹29 crore to ₹14 crore YoY.
- Customer concentration is a quarterly artifact: 93% quarterly revenue from top 10 reflects delivery schedule preponements and postponements; annual concentration runs 80–85%, with top 3 customers in proportionate historical range.
- Other Income drag: Total revenue growth was dented by negative Other Income from revaluation of USD-denominated borrowings after sharp INR depreciation, a non-cash item.
Vishal Thakkar: "There is a strong upward bias on the growth trajectory that we can see here."
Margin Structure & Sustainability
- Cost-plus contracts insulate margins: All costs (raw materials, freight, energy, commodities, inventory holding cost, overheads) pass through to customers, sustaining margins through the volatile environment.
- Pricing reset shortened: Significant contractual revenue (~60–70%) moved to 6-monthly pricing, improving the speed of cost pass-through.
- EBITDA margin guidance: Management sees 26–28% as a conservative sustainable range, with upward bias it declined to quantify.
- ROCE on recovery path: ROCE dropped from 30–35%+ because of ~₹800 cr CAPEX on a ~₹340 cr revenue base, including ~₹200 cr in non-revenue generating assets. Both ROCE and ROE now trending upward as assets get sweated.
Anand S Desai: "As you are aware that our contract is structured on a cost-plus basis. Now, when I say cost plus, all costs including raw materials, freight, energy, commodities, inventory holding cost, and other overheads are on a passthrough basis."
Fluorination: The Pipeline Opportunity
- 14 molecules, $220–260 mn potential: Identified for commercialization over the next 2–3 years, with annual revenue potential at full ramp.
- 5 molecules commercializing this year: Their revenue potential is in similar proportion to the 14-molecule basket, using existing plant capacity with no additional CAPEX required right now.
- R&D build-out underway: 8 professionals added in Q1, taking R&D strength to 85; senior technical professionals onboarded specifically in fluorination chemistry.
- No domestic competition framing: Management sees the opportunity as India vs. Europe, not intra-India rivalry, as customers shift demand from Europe to India.
Vishal Thakkar: "We have identified around 14 new molecules which we are looking at commercializing in the next 2 to 3 years' time period, and this on a potential basis as we had mentioned that we are looking at $220-260 million of revenue on an annual basis when they are fully ramped up."
Working Capital & Inventory
- Strategic inventory build: During Q4 FY22 supply disruption, MNC customers specifically asked Anupam to hold inventory as their partner, inflating working capital as a deliberate strategic call that is now helping increase wallet share.
- No price or volume risk: Customers acknowledge the cost at which inventory was acquired and pay carrying cost; management states there is no price risk or volume risk on the stock.
- Inventory days declining: A downward trajectory is already visible, with significant reduction expected by year-end.
Vishal Thakkar: "If you look at it from an inventory side, we do not have a price risk as well as we do not have volume risk. We know that they are going to offtake in this timeframe and we are comfortable and the customers have clearly communicated to us that we would be acknowledging the cost at which we have acquired."
Tanfac Integration & Expansion
- Integration progressing: Finance, IT, and HR systems successfully integrated; capacity of certain Tanfac products expanded through process improvement and debottlenecking.
- Acquisition structure: 25.8% stake acquired for ₹154 crores via open offer; management control changed by replacing Aditya Birla Group in the TIDCO JV.
- Self-funded expansion: Any expansion CAPEX at Tanfac will come from Tanfac's own balance sheet, not Anupam's.
CAPEX & Balance Sheet
- FY23 CAPEX: ~₹250 crore, majority for brownfield expansion at Jhagadia to monetize LOIs worth ₹2,620 crore, with higher asset turnover and incremental ROCE expected.
- LOI revenue ramp: ~₹450–500 crore annual revenue expected from LOI contracts; two molecules already supplied last year, two commercializing this year, two next year.
- Solar power savings: Additional 5.4 MW solar plant commissioning by Q2; combined savings of ₹14 crore per annum from FY24 onwards.
- FY24 CAPEX and debt: Management declined to provide FY24 CAPEX or debt guidance, calling debt forecasting "crystal ball gazing."
- Tax rate: FY24 onwards, tax rate expected around 25–30%, depending on MAT and other credits.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 26–28% on a conservative basis, with upward bias | Coming quarters |
| Revenue growth trajectory | Similar to last 2–3 years | FY23 |
| Fluorination commercialization | 5 molecules from existing capacity | FY23 |
| Fluorination pipeline | 14 molecules, $220–260 mn annual revenue potential | 2–3 years |
| LOI revenue ramp | ₹450–500 cr annual revenue from 6 molecules | Ramping; 2 molecules this year, 2 next year |
| Inventory days | Significant reduction | By year-end |
| ROCE | ~14% this year is what we are targeting, further upside as assets get utilized | FY23 |
| Solar power | Additional 5.4 MW, ₹14 cr annual savings | Commissioning by Q2; savings from FY24 |
| Tax rate | 25–30% | FY24 onwards |
| CAPEX | ~₹250 cr for LOI monetization | FY23 |
| 7 molecules in $10 mn+ list | 4 existing + 3 new, per customer forecasts | FY23 |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Operating revenue | ₹306.6 cr, +31% YoY |
| Total revenues | ₹297.1 cr, +25% YoY; impacted by negative Other Income from USD borrowing revaluation |
| EBITDA (incl. other revenues) | ₹84.5 cr, +30% YoY |
| EBITDA margin | 28%, expansion of 112 bps YoY |
| Profit after tax | ₹39.7 cr |
| Life Science segment revenue | ~₹290 cr, vs ~₹205 cr in Q1 FY22; 95% of total revenue |
| Other Specialty Chemicals revenue | ~₹14 cr, vs ~₹29 cr in Q1 FY22 |
| Revenue growth split | Fairly divided between volume and price |
| EBITDA margin guidance | 26% to 28% on a conservative basis, with upward bias |
| FY23 CAPEX plan | ~₹250 cr, brownfield expansion at Jhagadia for LOI demand |
| LOIs signed (FY22) | ₹2,620 cr worth, with ~₹450–500 cr annual revenue expected when ramped |
| Capacity utilization | 80% to 85% |
| Japan revenue contribution | 13% of revenues, up from 1% in 2018 |
| R&D team strength | 85 professionals, added 8 during the quarter |
| Pricing mechanism revision | 60% to 70% of significant contractual revenue moved to 6-monthly pricing |
| ROCE target | ~14% for the year |
| Tax rate expectation (FY24 onwards) | 25% to 30% |
| Fluorination molecules identified | 14 molecules, annual revenue potential of $220–260 million when fully ramped up |
| Fluorination molecules commercializing this year | 5 molecules |
| Molecules in $10+ million list | 7 molecules (4 from FY22 plus 3 additional) |
| Top 10 customer concentration (annual) | 80% to 85% of revenues |
| Solar power savings | Over ₹10 cr per annum from 12.5 MW plant; combined ₹14 cr per annum from FY24 with additional 5.4 MW |
| Cash on books | ~₹200 cr, sufficient for planned FY23 CAPEX |
| Tanfac stake acquisition cost | ₹154 cr for 25.8% stake |